nuclear receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Prognosis varies with the type of amyloidosis and the affected organ system. Prognosis for untreated AL cardiac amyloidosis is poor, with a median survival of six months. More specifically, AL amyloidosis can be classified as stage I, II or III based on cardiac biomarkers like Nt-proBNP and cardiac troponin. Survival diminishes with increasing stage, but recent advancements in treatments have improved median survival rates for stages I, II, and III, to 91.2, 60, and 7 months respectively. Outcomes in a person with AA amyloidosis depend on the underlying disease, organ(s) affected, and correlate with the concentration of serum amyloid A protein. People with ATTR, mutant ATTR and wild-type ATTR have a better prognosis when compared to people with AL and may survive for over a decade. Survival time is not associated with gender or age, however, some measures of reduced heart function are associated with a shorter survival time. Senile systemic amyloidosis was determined to be the primary cause of death for 70% of people over 110 who have been autopsied.
In another 2018 experiment, it was possible to perform a first laser-spectroscopic characterization of the nuclear properties of 229mTh. In this experiment, laser spectroscopy of the 229Th atomic shell was conducted using a 229Th2+ ion cloud with 2% of the ions in the nuclear excited state. This allowed probing for the hyperfine shift induced by the different nuclear spin states of the ground and the isomeric state. In this way, a first experimental value for the magnetic dipole and the electric quadrupole moment of 229mTh could be inferred. In 2019, the isomer's excitation energy was constrained to 8.28±0.17 eV based on the direct detection of internal conversion electrons and a secure population of 229mTh from the nuclear ground state was achieved by excitation of the 29 keV nuclear excited state via synchrotron radiation. Additional measurements by a different group in 2020 produced a figure of 8.10±0.17 eV (153.1±3.2 nm wavelength). Combining these measurements, the expected transition energy is 8.12±0.11 eV. In September 2022, spectroscopy on decaying samples determined the excitation energy to be 8.338±0.024 eV. In April 2024, two separate groups finally reported precision laser excitation Th4+ cations doped into ionic crystals (of CaF2 and LiSrAlF6 with additional interstitial F− anions for charge compensation), giving a precise (~1 part per million) measurement of the transition energy.
=== Cardiac === The apelin receptor is expressed early during the embryonic development of the heart, where it regulates the migration of cell progenitors fated to differentiate into cardiomyocytes, the contractile cells of the heart. Its expression is also detected in the cardiomyocytes of the adult where apelin behaves as one of the most potent stimulator of cardiac contractility. Aged apelin knockout mice develop progressive impairment of cardiac contractility. Apelin acts as a mediator of the cardiovascular control, including for blood pressure and blood flow. It is one of the most potent stimulators of cardiac contractility yet identified, and plays a role in cardiac tissue remodeling. Apelin levels are increased in left ventricles of patients with chronic heart failure and also in patients with chronic liver disease.
Sources: en.wikipedia.org
Once mRNA decoding is complete, the aminoacyl-tRNA is bound in the A/A site and is ready for the next peptide bond to be formed to its attached amino acid. The peptidyl-tRNA, which transfers the growing polypeptide to the aminoacyl-tRNA bound in the A/A site, is bound in the P/P site. Once the peptide bond is formed, the tRNA in the P/P site is acylated, or has a free 3' end, and the tRNA in the A/A site dissociates the growing polypeptide chain. To allow for the next elongation cycle, the tRNAs then move through hybrid A/P and P/E binding sites, before completing the cycle and residing in the P/P and E/E sites. Once the A/A and P/P tRNAs have moved to the P/P and E/E sites, the mRNA has also moved over by one codon and the A/T site is vacant, ready for the next round of mRNA decoding. The tRNA bound in the E/E site then leaves the ribosome. The P/I site is actually the first to bind to aminoacyl tRNA, which is delivered by an initiation factor called IF2 in bacteria. However, the existence of the P/I site in eukaryotic or archaeal ribosomes has not yet been confirmed. The P-site protein L27 has been determined by affinity labeling by E. Collatz and A. P. Czernilofsky (FEBS Lett., Vol. 63, pp. 283–286, 1976).
It got to a point where he'd kept himself so locked up, both physically and emotionally. I kept trying to make contact...Three times a week, like clockwork, I'd call him, but he'd never answer. Every time I was in the area, I was up in front of his place yelling for him ... Even if you could get in his building, he wasn't going to open the door. You'd phone and he wouldn't answer. You couldn't just kick the door in and grab him, though there were so many times I thought about doing that. But if someone won't help themselves, what, really, can anyone else do? Staley's physical appearance had become even worse than before: he had lost several teeth, his skin was sickly pale, and he was severely emaciated. Close friends such as Matt Fox said, "If no one heard from him for weeks, it wasn't unusual". Staley grew increasingly disconnected from his friends and bandmates who repeatedly tried to get him into rehab, but Staley refused. Staley's close friend Mark Lanegan said, "He didn't speak to anybody as of late... It's been a few months since I talked to him. But for us to not talk for a few months is par for the course."
== History == Omaveloxolone is a second generation member of the synthetic oleanane triterpenoid compounds and in clinical development by Reata Pharmaceuticals. Preclinical studies have demonstrated that omaveloxolone possesses antioxidative and anti-inflammatory activities and the ability to improve mitochondrial bioenergetics. Omaveloxolone is under clinical investigation for a variety of indications, including Friedreich's ataxia, mitochondrial myopathies, immunooncology, and prevention of corneal endothelial cell loss following cataract surgery. The efficacy and safety of omaveloxolone was evaluated in a 48-week randomized, placebo-controlled, and double-blind study [Study 1 (NCT02255435)] and an open-label extension. Study 1 enrolled 103 individuals with Friedreich's ataxia who received placebo (52 individuals) or omaveloxolone 150 mg (51 individuals) for 48 weeks. Of the research participants, 53% were male, 97% were white, and the mean age was 24 years at study entry. Nine (18%) patients were younger than age 18. The primary objective was to evaluate the change in the modified Friedreich's Ataxia Rating Scale (mFARS) score compared to placebo at week 48. The mFARS is a clinical assessment that measures disease progression, namely swallowing and speech (bulbar), upper limb coordination, lower limb coordination, and upright stability. Individuals receiving omaveloxolone performed better on the mFARS than people receiving placebo.
=== Russia === The Association of Medical Physicists in Russia is organized and operates [1]. Teaching of medical physics is carried out at Moscow State University, Moscow Institute of Physics and Technology [2], Kuban State University. The scientific journal "Medical Physics" is published [3].
Sources: en.wikipedia.org
Bats are placental mammals. After rodents, they are the largest order, making up about 20% of known mammal species. In 1758, Carl Linnaeus classified the seven bat species he knew of in the genus Vespertilio in the order Primates. Around twenty years later, the German naturalist Johann Friedrich Blumenbach gave them their own order, Chiroptera. Since then, the number of described species has risen to over 1,500, traditionally classified as two suborders: Megachiroptera (megabats) and Microchiroptera (microbats/echolocating bats). Not all megabats are larger than microbats. Several characteristics distinguish the two groups. Microbats use echolocation for navigation and finding prey, but megabats, apart from those in the genus Rousettus, do not. Accordingly, megabats have well-developed eyesight. Megabats have a claw on the second finger of the forelimb, external ears close to form a ring, and lack a tail. They only feed on plant material like fruit and nectar.
The vagina extends upward from the aperture and becomes the egg gland. In some jawless fish, there is neither oviduct nor vagina and instead the egg travels directly through the body cavity (and is fertilised externally as in most fish and amphibians). In insects and other invertebrates, the vagina can be a part of the oviduct (see insect reproductive system). Birds have a cloaca into which the urinary, reproductive tract (vagina) and gastrointestinal tract empty. Females of some waterfowl species have developed vaginal structures called dead end sacs and clockwise coils to protect themselves from sexual coercion. A lack of research on the vagina and other female genitalia, especially for different animals, has stifled knowledge on female sexual anatomy. One explanation for why male genitalia is studied more includes penises being significantly simpler to analyze than female genital cavities, because male genitals usually protrude and are therefore easier to assess and measure. By contrast, female genitals are more often concealed, and require more dissection, which in turn requires more time. Another explanation is that a main function of the penis is to impregnate, while female genitals may alter shape upon interaction with male organs, especially as to benefit or hinder reproductive success. Non-human primates are optimal models for human biomedical research because humans and non-human primates share physiological characteristics as a result of evolution.
== History == In 1863, German chemists Ferdinand Reich and Hieronymus Theodor Richter were testing ores from the mines around Freiberg, Saxony. They dissolved the minerals pyrite, arsenopyrite, galena and sphalerite in hydrochloric acid and distilled raw zinc chloride. Reich, who was color-blind, employed Richter as an assistant for detecting the colored spectral lines. Knowing that ores from that region sometimes contain thallium, they searched for the green thallium emission spectrum lines. Instead, they found a bright blue line. Because that blue line did not match any known element, they hypothesized a new element was present in the minerals. They named the element indium, from the indigo color seen in its spectrum, after the Latin indicum, meaning 'of India'. Richter went on to isolate the metal in 1864. An ingot of 0.5 kg (1.1 lb) was presented at the World Fair 1867. Reich and Richter later fell out when Richter claimed to be the sole discoverer.
Many AI systems are so complex that their designers cannot explain how they reach their decisions. Particularly with deep neural networks, in which there are many non-linear relationships between inputs and outputs. But some popular explainability techniques exist. It is impossible to be certain that a program is operating correctly if no one knows how exactly it works. There have been many cases where a machine learning program passed rigorous tests, but nevertheless learned something different from what the programmers intended. For example, a system that could identify skin diseases better than medical professionals was found to actually have a strong tendency to classify images with a ruler as "cancerous", because pictures of malignancies typically include a ruler to show the scale. Another machine learning system designed to help effectively allocate medical resources was found to classify patients with asthma as being at "low risk" of dying from pneumonia. Having asthma is actually a severe risk factor, but since the patients having asthma would usually get much more medical care, they were relatively unlikely to die according to the training data. The correlation between asthma and low risk of dying from pneumonia was real, but misleading. People who have been harmed by an algorithm's decision have a right to an explanation. Doctors, for example, are expected to clearly and completely explain to their colleagues the reasoning behind any decision they make.
Kort & Ricker (2026) compare pelvic morphology of Sinopa and Thinocyon with those of extant mammals, and argue that extant carnivorans might be imperfect analogs for reconstructions of configuration of musculature and locomotor modes of hyaenodonts. Fischer et al. (2026) study the body mass evolution in European mesonychians, hyaenodonts, oxyaenodonts and carnivoramorphs during the Paleogene, reporting evidence of increase of range of body mass of members of Carnivoramorpha after the Middle Eocene Climatic Optimum (and before the establishment of carnivoran-dominated faunas related to the Grande Coupure), and interpret the replacement of hyaenodont-dominated faunas in Europe by carnivoran-dominated ones as more likely related to climate changes than caused by competition between the different group of mammalian carnivores.
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.